{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:43:29Z","timestamp":1794951809334,"version":"4.9.1"},"reference-count":231,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Proced Online"],"DOI":"10.1186\/s12575-025-00269-2","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T10:31:59Z","timestamp":1748946719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses"],"prefix":"10.1186","volume":"27","author":[{"given":"Rafid Jihad","family":"Albadr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder Naji","family":"Sameer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab H.","family":"Athab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohaned","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Yaseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer Qutaiba B.","family":"Allela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"269_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.virusres.2018.02.016","volume":"248","author":"R Bartenschlager","year":"2018","unstructured":"Bartenschlager R, et al. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: considerations for scientists and funding agencies. Virus Res. 2018;248:53\u201362.","journal-title":"Virus Res"},{"issue":"1","key":"269_CR2","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","volume":"65","author":"H Midgard","year":"2016","unstructured":"Midgard H, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65(1):S33\u201345.","journal-title":"J Hepatol"},{"issue":"5","key":"269_CR3","doi-asserted-by":"publisher","first-page":"e0156213","DOI":"10.1371\/journal.pone.0156213","volume":"11","author":"J Stone","year":"2016","unstructured":"Stone J, et al. The potential impact of a hepatitis C vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals? PLoS ONE. 2016;11(5):e0156213.","journal-title":"PLoS ONE"},{"issue":"3","key":"269_CR4","doi-asserted-by":"publisher","first-page":"a021402","DOI":"10.1101\/cshperspect.a021402","volume":"6","author":"BL Slagle","year":"2016","unstructured":"Slagle BL, Bouchard MJ. Hepatitis B virus X and regulation of viral gene expression. Cold Spring Harbor Perspect Med. 2016;6(3):a021402.","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"269_CR5","unstructured":"Tu T et al. Hepatitis B virus DNA integration occurs early in the viral life cycle in an. Vitro."},{"issue":"12","key":"269_CR6","first-page":"3676","volume":"8","author":"AM Kaufmann","year":"2002","unstructured":"Kaufmann AM, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 2002;8(12):3676\u201385.","journal-title":"Clin Cancer Res"},{"key":"269_CR7","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00262-012-1292-7","volume":"61","author":"PJ de Vos","year":"2012","unstructured":"de Vos PJ, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother. 2012;61:1485\u201392.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"269_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/cgt.2013.65","volume":"20","author":"N Obeng-Adjei","year":"2013","unstructured":"Obeng-Adjei N, et al. DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques. Cancer Gene Ther. 2013;20(12):652\u201362.","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"269_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/mt.2013.274","volume":"22","author":"O Godon","year":"2014","unstructured":"Godon O, et al. Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther. 2014;22(3):675\u201384.","journal-title":"Mol Ther"},{"key":"269_CR10","doi-asserted-by":"crossref","unstructured":"Kelly C et al. A therapeutic vaccine for HCV based on novel, rare, adenoviral vectors. 2011.","DOI":"10.1016\/S0168-8278(11)60067-6"},{"issue":"8","key":"269_CR11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.cgh.2017.11.045","volume":"16","author":"G Cholankeril","year":"2018","unstructured":"Cholankeril G, Ahmed A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2018;16(8):1356.","journal-title":"Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association"},{"issue":"2","key":"269_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/v14020401","volume":"14","author":"T Le","year":"2022","unstructured":"Le T, et al. mRNA vaccine development for emerging animal and zoonotic diseases. Viruses. 2022;14(2):401.","journal-title":"Viruses"},{"issue":"1","key":"269_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-022-01625-0","volume":"20","author":"S Yasamineh","year":"2022","unstructured":"Yasamineh S, et al. An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19. J Nanobiotechnol. 2022;20(1):1\u201326.","journal-title":"J Nanobiotechnol"},{"key":"269_CR14","doi-asserted-by":"publisher","first-page":"103968","DOI":"10.1016\/j.meegid.2019.103968","volume":"75","author":"S Karimkhanilouyi","year":"2019","unstructured":"Karimkhanilouyi S, Ghorbian S. Nucleic acid vaccines for hepatitis B and C virus. Infect Genet Evol. 2019;75:103968.","journal-title":"Infect Genet Evol"},{"issue":"1","key":"269_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41541-024-00813-3","volume":"9","author":"H Zhao","year":"2024","unstructured":"Zhao H, et al. A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. npj Vaccines. 2024;9(1):22.","journal-title":"npj Vaccines"},{"issue":"2","key":"269_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00103-021-03472-0","volume":"65","author":"D Bender","year":"2021","unstructured":"Bender D, Glitscher M, Hildt E. Viral hepatitis A to E: prevalence, pathogen characteristics, and pathogenesis. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021;65(2):139\u201348.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"9","key":"269_CR17","doi-asserted-by":"publisher","first-page":"a033472","DOI":"10.1101\/cshperspect.a033472","volume":"9","author":"CM Walker","year":"2019","unstructured":"Walker CM. Adaptive immune responses in hepatitis a virus and hepatitis E virus infections. Cold Spring Harbor Perspect Med. 2019;9(9):a033472.","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"1","key":"269_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/molecules22010148","volume":"22","author":"EM Flefel","year":"2017","unstructured":"Flefel EM, et al. Synthesis of some new pyridazine derivatives for anti-HAV evaluation. Molecules. 2017;22(1):148.","journal-title":"Molecules"},{"issue":"20","key":"269_CR19","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.3748\/wjg.v23.i20.3589","volume":"23","author":"K-Y Lin","year":"2017","unstructured":"Lin K-Y, et al. Hepatitis A virus infection and hepatitis a vaccination in human immunodeficiency virus-positive patients: a review. World J Gastroenterol. 2017;23(20):3589.","journal-title":"World J Gastroenterol"},{"key":"269_CR20","first-page":"67","volume-title":"Update: recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for postexposure prophylaxis and for preexposure prophylaxis for international travel","author":"NP Nelson","year":"2018","unstructured":"Nelson NP. Update: recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for postexposure prophylaxis and for preexposure prophylaxis for international travel. MMWR. Morbidity and Mortality Weekly Report; 2018. p. 67."},{"issue":"1","key":"269_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jcv.2012.01.009","volume":"54","author":"L Bordi","year":"2012","unstructured":"Bordi L, et al. Monophyletic outbreak of Hepatitis A involving HIV-infected men who have sex with men, Rome, Italy 2008\u20132009. J Clin Virol. 2012;54(1):26\u20139.","journal-title":"J Clin Virol"},{"key":"269_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.meegid.2013.10.023","volume":"21","author":"G Vaughan","year":"2014","unstructured":"Vaughan G, et al. Hepatitis A virus: host interactions, molecular epidemiology and evolution. Infect Genet Evol. 2014;21:227\u201343.","journal-title":"Infect Genet Evol"},{"issue":"10","key":"269_CR23","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.3390\/v13101900","volume":"13","author":"M Migueres","year":"2021","unstructured":"Migueres M, Lhomme S, Izopet J. Hepatitis A: epidemiology, high-risk groups, prevention and research on antiviral treatment. Viruses. 2021;13(10):1900.","journal-title":"Viruses"},{"issue":"2","key":"269_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00103-021-03478-8","volume":"65","author":"S Dudareva","year":"2022","unstructured":"Dudareva S, et al. Epidemiology of viral hepatitis A to E in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022;65(2):149\u201358.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"4","key":"269_CR25","doi-asserted-by":"publisher","first-page":"6842","DOI":"10.3390\/ijms16046842","volume":"16","author":"L D\u2019Andrea","year":"2015","unstructured":"D\u2019Andrea L, et al. Hepatitis A virus genotype distribution during a decade of universal vaccination of preadolescents. Int J Mol Sci. 2015;16(4):6842\u201354.","journal-title":"Int J Mol Sci"},{"issue":"28","key":"269_CR26","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.3748\/wjg.v27.i28.4603","volume":"27","author":"P Torre","year":"2021","unstructured":"Torre P, et al. Viral hepatitis: milestones, unresolved issues, and future goals. World J Gastroenterol. 2021;27(28):4603.","journal-title":"World J Gastroenterol"},{"key":"269_CR27","first-page":"a031815","volume-title":"Nonhuman primate models of hepatitis A virus and hepatitis E virus infections","author":"RE Lanford","year":"2019","unstructured":"Lanford RE, Walker CM, Lemon SM. Nonhuman primate models of hepatitis a virus and hepatitis E virus infections. Volume 9. Cold Spring Harbor perspectives in medicine; 2019. p. a031815. 2."},{"issue":"10","key":"269_CR28","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.7150\/ijms.32795","volume":"16","author":"NN Win","year":"2019","unstructured":"Win NN, et al. Superinfection of Hepatitis A virus in hepatocytes infected with hepatitis B virus. Int J Med Sci. 2019;16(10):1366.","journal-title":"Int J Med Sci"},{"issue":"3","key":"269_CR29","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jhep.2019.05.011","volume":"72","author":"N Gotlieb","year":"2020","unstructured":"Gotlieb N, Moradpour D, Shouval D. Hepatitis A and E\u2013differences and commonalities. J Hepatol. 2020;72(3):578\u201380.","journal-title":"J Hepatol"},{"issue":"1","key":"269_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12934-022-01780-x","volume":"21","author":"A Nain","year":"2022","unstructured":"Nain A, Kumar M, Banerjee M. Oligomers of hepatitis a virus (HAV) capsid protein VP1 generated in a heterologous expression system. Microb Cell Fact. 2022;21(1):53.","journal-title":"Microb Cell Fact"},{"key":"269_CR31","doi-asserted-by":"crossref","unstructured":"Gholizadeh O, Akbarzadeh S. Hepatitis A: Viral Structure, Classification, Life Cycle, Clinical Symptoms, Diagnosis Error, and Vaccination. 2023. 2023: p. 4263309.","DOI":"10.1155\/2023\/4263309"},{"issue":"1","key":"269_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41572-023-00461-2","volume":"9","author":"P Van Damme","year":"2023","unstructured":"Van Damme P, et al. Hepatitis A virus infection. Nat Reviews Disease Primers. 2023;9(1):51.","journal-title":"Nat Reviews Disease Primers"},{"issue":"5","key":"269_CR33","first-page":"457","volume":"7","author":"M-A Mahtab","year":"2008","unstructured":"Mahtab M-A, et al. Hepatitis B virus genotypes: an overview. Hepatobiliary Pancreat Dis International: HBPD INT. 2008;7(5):457\u201364.","journal-title":"Hepatobiliary Pancreat Dis International: HBPD INT"},{"issue":"3","key":"269_CR34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/jmv.21978","volume":"83","author":"CH Nguyen","year":"2011","unstructured":"Nguyen CH, et al. Prevalence of HBV infection among different HIV-risk groups in Hai Phong, Vietnam. J Med Virol. 2011;83(3):399\u2013404.","journal-title":"J Med Virol"},{"issue":"3","key":"269_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41594-023-01191-5","volume":"31","author":"J Asami","year":"2024","unstructured":"Asami J, et al. Structural basis of hepatitis B virus receptor binding. Nat Struct Mol Biol. 2024;31(3):447\u201354.","journal-title":"Nat Struct Mol Biol"},{"issue":"24","key":"269_CR36","doi-asserted-by":"publisher","first-page":"7420","DOI":"10.3390\/molecules26247420","volume":"26","author":"H Kim","year":"2021","unstructured":"Kim H, et al. Current progress in the development of hepatitis B virus capsid assembly modulators: chemical structure, mode-of-action and efficacy. Molecules. 2021;26(24):7420.","journal-title":"Molecules"},{"issue":"9","key":"269_CR37","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3390\/v16091361","volume":"16","author":"D Li","year":"2024","unstructured":"Li D, Hamadalnil Y, Tu T. Hepatitis B viral protein HBx: roles in viral replication and Hepatocarcinogenesis. Viruses. 2024;16(9):1361.","journal-title":"Viruses"},{"issue":"10","key":"269_CR38","doi-asserted-by":"publisher","first-page":"e1008945","DOI":"10.1371\/journal.ppat.1008945","volume":"16","author":"S Shen","year":"2020","unstructured":"Shen S, et al. Biogenesis and molecular characteristics of serum hepatitis B virus RNA. PLoS Pathog. 2020;16(10):e1008945.","journal-title":"PLoS Pathog"},{"key":"269_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-018-0926-4","volume":"19","author":"Y Liu","year":"2019","unstructured":"Liu Y, et al. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol. 2019;19:1\u20139.","journal-title":"BMC Gastroenterol"},{"key":"269_CR40","doi-asserted-by":"crossref","unstructured":"Bai L et al. Extracellular HBV RNAs are heterogeneous in length and circulate as virions and capsid-antibody-complexes in chronic hepatitis B patients. bioRxiv, 2018: p. 320994.","DOI":"10.1101\/320994"},{"issue":"9959","key":"269_CR41","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053\u201363.","journal-title":"Lancet"},{"issue":"1","key":"269_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/jgh.13030","volume":"31","author":"K Ito","year":"2016","unstructured":"Ito K, et al. Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. J Gastroenterol Hepatol. 2016;31(1):180\u20139.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"269_CR43","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","volume":"64","author":"S Tong","year":"2016","unstructured":"Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol. 2016;64(1):S4\u201316.","journal-title":"J Hepatol"},{"issue":"6","key":"269_CR44","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1046\/j.1440-1746.2002.02737.x","volume":"17","author":"JH KAO","year":"2002","unstructured":"KAO JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol. 2002;17(6):643\u201350.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"269_CR45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1440-1746.2008.05384.x","volume":"23","author":"CJ Chu","year":"2008","unstructured":"Chu CJ, Lee SD. Hepatitis B virus\/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23(4):512\u201320.","journal-title":"J Gastroenterol Hepatol"},{"key":"269_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-10-214","volume":"10","author":"L Li","year":"2013","unstructured":"Li L, et al. Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B. Virol J. 2013;10:1\u201315.","journal-title":"Virol J"},{"key":"269_CR47","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00705-010-0628-x","volume":"155","author":"Mulyanto","year":"2010","unstructured":"Mulyanto, et al. Identification and characterization of novel hepatitis B virus subgenotype C10 in Nusa Tenggara, Indonesia. Arch Virol. 2010;155:705\u201315.","journal-title":"Arch Virol"},{"issue":"1","key":"269_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.virusres.2011.09.002","volume":"163","author":"P Pancawardani","year":"2012","unstructured":"Pancawardani P, et al. Identification of four novel subgenotypes (C13\u2013C16) and two inter-genotypic recombinants (C12\/G and C13\/B3) of hepatitis B virus in Papua province, Indonesia. Virus Res. 2012;163(1):129\u201340.","journal-title":"Virus Res"},{"issue":"2","key":"269_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis. 2004;11(2):97\u2013107.","journal-title":"J Viral Hepatitis"},{"issue":"1","key":"269_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3748\/wjg.v13.i1.65","volume":"13","author":"V Bruss","year":"2007","unstructured":"Bruss V. Hepatitis B virus morphogenesis. World J Gastroenterology: WJG. 2007;13(1):65.","journal-title":"World J Gastroenterology: WJG"},{"key":"269_CR51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coviro.2018.01.007","volume":"30","author":"BL Slagle","year":"2018","unstructured":"Slagle BL, Bouchard MJ. Role of HBx in hepatitis B virus persistence and its therapeutic implications. Curr Opin Virol. 2018;30:32\u20138.","journal-title":"Curr Opin Virol"},{"issue":"9","key":"269_CR52","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/jvh.12387","volume":"22","author":"N D\u00e9sir\u00e9","year":"2015","unstructured":"D\u00e9sir\u00e9 N, et al. Definition of an HB sAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms. J Viral Hepatitis. 2015;22(9):718\u201326.","journal-title":"J Viral Hepatitis"},{"issue":"3","key":"269_CR53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/v9030056","volume":"9","author":"J Hu","year":"2017","unstructured":"Hu J, Liu K. Complete and incomplete hepatitis B virus particles: formation, function, and application. Viruses. 2017;9(3):56.","journal-title":"Viruses"},{"issue":"9","key":"269_CR54","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/v12090998","volume":"12","author":"GS Duraisamy","year":"2020","unstructured":"Duraisamy GS, et al. Advanced therapeutics, vaccinations, and precision medicine in the treatment and management of chronic hepatitis b viral infections; where are we and where are we going? Viruses. 2020;12(9):998.","journal-title":"Viruses"},{"issue":"10","key":"269_CR55","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41575-020-0296-6","volume":"17","author":"PA Revill","year":"2020","unstructured":"Revill PA, et al. The evolution and clinical impact of hepatitis B virus genome diversity. Nat Reviews Gastroenterol Hepatol. 2020;17(10):618\u201334.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"6","key":"269_CR56","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/cid\/ciac139","volume":"75","author":"EH Teshale","year":"2022","unstructured":"Teshale EH, et al. Characteristics of persons treated for hepatitis C using national pharmacy claims data, United States, 2014\u20132020. Clin Infect Dis. 2022;75(6):1078\u201380.","journal-title":"Clin Infect Dis"},{"key":"269_CR57","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.virol.2014.07.026","volume":"468","author":"C Li","year":"2014","unstructured":"Li C, et al. The genetic diversity and evolutionary history of hepatitis C virus in Vietnam. Virology. 2014;468:197\u2013206.","journal-title":"Virology"},{"issue":"4","key":"269_CR58","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","volume":"56","author":"LP Bechmann","year":"2012","unstructured":"Bechmann LP, et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56(4):952\u201364.","journal-title":"J Hepatol"},{"issue":"5","key":"269_CR59","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"J-M Pawlotsky","year":"2020","unstructured":"Pawlotsky J-M, et al. EASL recommendations on treatment of hepatitis C: final update of the series\u2606. J Hepatol. 2020;73(5):1170\u2013218.","journal-title":"J Hepatol"},{"key":"269_CR60","doi-asserted-by":"publisher","first-page":"379597","DOI":"10.3389\/fimmu.2018.01315","volume":"9","author":"N Tzarum","year":"2018","unstructured":"Tzarum N, Wilson IA, Law M. The neutralizing face of hepatitis C virus E2 envelope glycoprotein. Front Immunol. 2018;9:379597.","journal-title":"Front Immunol"},{"issue":"6","key":"269_CR61","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.meegid.2010.04.010","volume":"10","author":"Y-s Liu","year":"2010","unstructured":"Liu Y-s, et al. Analysis of synonymous codon usage in porcine reproductive and respiratory syndrome virus. Infect Genet Evol. 2010;10(6):797\u2013803.","journal-title":"Infect Genet Evol"},{"issue":"5","key":"269_CR62","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.meegid.2011.02.018","volume":"11","author":"Y-s Liu","year":"2011","unstructured":"Liu Y-s, et al. The characteristics of the synonymous codon usage in enterovirus 71 virus and the effects of host on the virus in codon usage pattern. Infect Genet Evol. 2011;11(5):1168\u201373.","journal-title":"Infect Genet Evol"},{"issue":"8","key":"269_CR63","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.meegid.2011.08.025","volume":"11","author":"J-s Hu","year":"2011","unstructured":"Hu J-s, et al. The characteristic of codon usage pattern and its evolution of hepatitis C virus. Infect Genet Evol. 2011;11(8):2098\u2013102.","journal-title":"Infect Genet Evol"},{"key":"269_CR64","doi-asserted-by":"publisher","first-page":"114852","DOI":"10.1016\/j.jviromet.2023.114852","volume":"323","author":"K Izumida","year":"2024","unstructured":"Izumida K, et al. Purification of hepatitis C virus core protein in non-denaturing condition. J Virol Methods. 2024;323:114852.","journal-title":"J Virol Methods"},{"issue":"7","key":"269_CR65","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm.3248","volume":"19","author":"TK Scheel","year":"2013","unstructured":"Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013;19(7):837\u201349.","journal-title":"Nat Med"},{"issue":"13","key":"269_CR66","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.3748\/wjg.v20.i13.3457","volume":"20","author":"Y-Z Zhu","year":"2014","unstructured":"Zhu Y-Z, et al. How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterology: WJG. 2014;20(13):3457.","journal-title":"World J Gastroenterology: WJG"},{"issue":"6","key":"269_CR67","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jhep.2010.09.040","volume":"54","author":"J Torresi","year":"2011","unstructured":"Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011;54(6):1273\u201385.","journal-title":"J Hepatol"},{"issue":"38","key":"269_CR68","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","volume":"28","author":"SE Frey","year":"2010","unstructured":"Frey SE, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010;28(38):6367\u201373.","journal-title":"Vaccine"},{"issue":"5","key":"269_CR69","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","volume":"12","author":"J Grebely","year":"2012","unstructured":"Grebely J, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12(5):408\u201314.","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"269_CR70","doi-asserted-by":"publisher","first-page":"18904","DOI":"10.1074\/jbc.M113.538256","volume":"289","author":"A Boyer","year":"2014","unstructured":"Boyer A, et al. The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles. J Biol Chem. 2014;289(27):18904\u201313.","journal-title":"J Biol Chem"},{"issue":"16","key":"269_CR71","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1016\/j.jmb.2015.06.012","volume":"427","author":"L Kong","year":"2015","unstructured":"Kong L, et al. Structure of hepatitis C virus envelope glycoprotein E1 antigenic site 314\u2013324 in complex with antibody IGH526. J Mol Biol. 2015;427(16):2617\u201328.","journal-title":"J Mol Biol"},{"issue":"6250","key":"269_CR72","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1126\/science.aad1302","volume":"349","author":"AL Cox","year":"2015","unstructured":"Cox AL. Global control of hepatitis C virus. Science. 2015;349(6250):790\u20131.","journal-title":"Science"},{"issue":"5","key":"269_CR73","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/v16050803","volume":"16","author":"BG Pierce","year":"2024","unstructured":"Pierce BG, et al. Hepatitis C Virus E1E2 structure, diversity, and implications for Vaccine Development. Viruses. 2024;16(5):803.","journal-title":"Viruses"},{"issue":"9","key":"269_CR74","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","volume":"70","author":"S Urban","year":"2021","unstructured":"Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021;70(9):1782\u201394.","journal-title":"Gut"},{"issue":"3","key":"269_CR75","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","volume":"73","author":"AJ Stockdale","year":"2020","unstructured":"Stockdale AJ, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523\u201332.","journal-title":"J Hepatol"},{"issue":"1","key":"269_CR76","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","volume":"23","author":"H Wedemeyer","year":"2023","unstructured":"Wedemeyer H, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2023;23(1):117\u201329.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"269_CR77","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.cld.2021.06.011","volume":"25","author":"L Sandmann","year":"2021","unstructured":"Sandmann L, Wedemeyer H. New treatments for chronic hepatitis B virus\/hepatitis D virus infection. Clin Liver Dis. 2021;25(4):831\u20139.","journal-title":"Clin Liver Dis"},{"issue":"2","key":"269_CR78","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/HEP.0000000000000584","volume":"81","author":"H Wedemeyer","year":"2025","unstructured":"Wedemeyer H, et al. HDV RNA assays: performance characteristics, clinical utility, and challenges. Hepatology. 2025;81(2):637\u201350.","journal-title":"Hepatology"},{"issue":"3","key":"269_CR79","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jmv.23212","volume":"84","author":"L Shen","year":"2012","unstructured":"Shen L, et al. Development of a hepatitis delta virus antibody assay for study of the prevalence of HDV among individuals infected with hepatitis B virus in China. J Med Virol. 2012;84(3):445\u20139.","journal-title":"J Med Virol"},{"issue":"6","key":"269_CR80","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/hep.27742","volume":"61","author":"HH Lin","year":"2015","unstructured":"Lin HH, et al. Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. Hepatology. 2015;61(6):1870\u20139.","journal-title":"Hepatology"},{"issue":"2","key":"269_CR81","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1537-2995.2011.03283.x","volume":"52","author":"SL Stramer","year":"2012","unstructured":"Stramer SL, et al. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? Transfusion. 2012;52(2):440\u20136.","journal-title":"Transfusion"},{"issue":"1","key":"269_CR82","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/liv.14729","volume":"41","author":"M Rizzetto","year":"2021","unstructured":"Rizzetto M, Hamid S. The medical impact of hepatitis D virus infection in Asia and Africa; time for a reappraisal. Liver Int. 2021;41(1):16\u20139.","journal-title":"Liver Int"},{"issue":"4","key":"269_CR83","doi-asserted-by":"publisher","first-page":"e0250347","DOI":"10.1371\/journal.pone.0250347","volume":"16","author":"J Vieira Barbosa","year":"2021","unstructured":"Vieira Barbosa J, et al. Demographics and outcomes of hepatitis B and D: a 10-year retrospective analysis in a Swiss tertiary referral center. PLoS ONE. 2021;16(4):e0250347.","journal-title":"PLoS ONE"},{"issue":"8","key":"269_CR84","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/infdis\/jiaa517","volume":"223","author":"P Cappy","year":"2021","unstructured":"Cappy P, et al. No evidence of hepatitis C virus (HCV)\u2013Assisted hepatitis D virus propagation in a large cohort of HCV-positive blood donors. J Infect Dis. 2021;223(8):1376\u201380.","journal-title":"J Infect Dis"},{"issue":"4","key":"269_CR85","first-page":"203","volume":"22","author":"M Toy","year":"2020","unstructured":"Toy M, Ahishal\u0131 E, Yurdayd\u0131n C. Hepatitis Delta Virus Epidemiology in the Industrialized World. AIDS Rev, 2020. 22(4).","journal-title":"AIDS Rev"},{"issue":"5","key":"269_CR86","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jhep.2021.01.014","volume":"74","author":"M Rizzetto","year":"2021","unstructured":"Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol. 2021;74(5):1200\u201311.","journal-title":"J Hepatol"},{"issue":"10","key":"269_CR87","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/jnci\/djs168","volume":"104","author":"J Ji","year":"2012","unstructured":"Ji J, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst. 2012;104(10):790\u20132.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"269_CR88","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jmii.2015.10.013","volume":"50","author":"C-C Lin","year":"2017","unstructured":"Lin C-C, et al. RNA recombination in Hepatitis delta virus: identification of a novel naturally occurring recombinant. J Microbiol Immunol Infect. 2017;50(6):771\u201380.","journal-title":"J Microbiol Immunol Infect"},{"issue":"9","key":"269_CR89","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/j.1478-3231.2012.02831.x","volume":"32","author":"B Heidrich","year":"2012","unstructured":"Heidrich B, et al. HB eAg-positive hepatitis delta: virological patterns and clinical long\u2010term outcome. Liver Int. 2012;32(9):1415\u201325.","journal-title":"Liver Int"},{"issue":"4","key":"269_CR90","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","volume":"61","author":"Q Ning","year":"2014","unstructured":"Ning Q, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014;61(4):777\u201384.","journal-title":"J Hepatol"},{"issue":"4","key":"269_CR91","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jhep.2016.05.043","volume":"65","author":"J Petersen","year":"2016","unstructured":"Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol. 2016;65(4):835\u201348.","journal-title":"J Hepatol"},{"issue":"6","key":"269_CR92","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/liv.15387","volume":"43","author":"YC Tan","year":"2023","unstructured":"Tan YC, et al. Future anti-HDV treatment strategies, including those aimed at HBV functional cure. Liver Int. 2023;43(6):1157\u201369.","journal-title":"Liver Int"},{"issue":"3","key":"269_CR93","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/cid\/civ862","volume":"62","author":"Y Guillois","year":"2016","unstructured":"Guillois Y, et al. High proportion of asymptomatic infections in an outbreak of hepatitis E associated with a spit-roasted piglet, France, 2013. Clin Infect Dis. 2016;62(3):351\u20137.","journal-title":"Clin Infect Dis"},{"issue":"1\u20132","key":"269_CR94","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.virusres.2011.03.019","volume":"158","author":"W Batts","year":"2011","unstructured":"Batts W, et al. A novel member of the family Hepeviridae from cutthroat trout (Oncorhynchus clarkii). Virus Res. 2011;158(1\u20132):116\u201323.","journal-title":"Virus Res"},{"key":"269_CR95","doi-asserted-by":"publisher","first-page":"831968","DOI":"10.3389\/fmicb.2021.831968","volume":"12","author":"L Fang","year":"2022","unstructured":"Fang L, et al. Epidemiological characteristics and clinical manifestations of hepatitis E in a tertiary hospital in China: a retrospective study. Front Microbiol. 2022;12:831968.","journal-title":"Front Microbiol"},{"issue":"2","key":"269_CR96","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1128\/JVI.00657-10","volume":"85","author":"L Xing","year":"2011","unstructured":"Xing L, et al. Spatial configuration of hepatitis E virus antigenic domain. J Virol. 2011;85(2):1117\u201324.","journal-title":"J Virol"},{"issue":"10","key":"269_CR97","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/v8100270","volume":"8","author":"V Doceul","year":"2016","unstructured":"Doceul V, et al. Zoonotic hepatitis E virus: classification, animal reservoirs and transmission routes. Viruses. 2016;8(10):270.","journal-title":"Viruses"},{"issue":"10","key":"269_CR98","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1099\/vir.0.068429-0","volume":"95","author":"DB Smith","year":"2014","unstructured":"Smith DB, et al. Consensus proposals for classification of the family Hepeviridae. J Gen Virol. 2014;95(10):2223\u201332.","journal-title":"J Gen Virol"},{"issue":"2","key":"269_CR99","first-page":"117","volume":"3","author":"MT P\u00e9rez-Gracia","year":"2015","unstructured":"P\u00e9rez-Gracia MT, et al. Current knowledge on hepatitis E. J Clin Translational Hepatol. 2015;3(2):117.","journal-title":"J Clin Translational Hepatol"},{"issue":"26","key":"269_CR100","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.3748\/wjg.v27.i26.4018","volume":"27","author":"MB Pisano","year":"2021","unstructured":"Pisano MB, et al. Viral hepatitis update: progress and perspectives. World J Gastroenterol. 2021;27(26):4018.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"269_CR101","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3390\/microorganisms12071405","volume":"12","author":"F Jiao","year":"2024","unstructured":"Jiao F, et al. Multiple functions of Hepatitis E Virus ORF3. Microorganisms. 2024;12(7):1405.","journal-title":"Microorganisms"},{"issue":"11","key":"269_CR102","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/infdis\/jir631","volume":"204","author":"J-C Meunier","year":"2011","unstructured":"Meunier J-C, et al. Neutralizing antibodies to hepatitis C virus in perinatally infected children followed up prospectively. J Infect Dis. 2011;204(11):1741\u20135.","journal-title":"J Infect Dis"},{"issue":"6","key":"269_CR103","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1053\/j.gastro.2012.02.016","volume":"142","author":"J Bukh","year":"2012","unstructured":"Bukh J. Animal models for the study of hepatitis C virus infection and related liver disease. Gastroenterology. 2012;142(6):1279\u201387. e3.","journal-title":"Gastroenterology"},{"issue":"5","key":"269_CR104","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/infdis\/jir835","volume":"205","author":"S Raghuraman","year":"2012","unstructured":"Raghuraman S, et al. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis. 2012;205(5):763\u201371.","journal-title":"J Infect Dis"},{"issue":"23","key":"269_CR105","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMct061675","volume":"355","author":"JH Hoofnagle","year":"2006","unstructured":"Hoofnagle JH, Seeff LB. Peginterferon and Ribavirin for chronic hepatitis C. N Engl J Med. 2006;355(23):2444\u201351.","journal-title":"N Engl J Med"},{"issue":"6","key":"269_CR106","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2012.02.015","volume":"142","author":"EA Schaefer","year":"2012","unstructured":"Schaefer EA, Chung RT. Anti\u2009\u2013\u2009Hepatitis C Virus drugs in Development. Gastroenterology. 2012;142(6):1340\u201350. e1.","journal-title":"Gastroenterology"},{"issue":"3","key":"269_CR107","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1056\/NEJM199701163360307","volume":"336","author":"SM Lemon","year":"1997","unstructured":"Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997;336(3):196\u2013204.","journal-title":"N Engl J Med"},{"issue":"3","key":"269_CR108","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14740\/gr1405","volume":"14","author":"W Zhang","year":"2021","unstructured":"Zhang W, et al. A focused review on recent advances in the diagnosis and treatment of viral hepatitis. Gastroenterol Res. 2021;14(3):139.","journal-title":"Gastroenterol Res"},{"issue":"7","key":"269_CR109","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1365-2893.2010.01327.x","volume":"18","author":"WN Southern","year":"2011","unstructured":"Southern WN, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepatitis. 2011;18(7):474\u201381.","journal-title":"J Viral Hepatitis"},{"issue":"12","key":"269_CR110","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/jvh.13371","volume":"27","author":"Z Liu","year":"2020","unstructured":"Liu Z, et al. Disease burden of viral hepatitis A, B, C and E: a systematic analysis. J Viral Hepatitis. 2020;27(12):1284\u201396.","journal-title":"J Viral Hepatitis"},{"issue":"9","key":"269_CR111","doi-asserted-by":"publisher","first-page":"a031880","DOI":"10.1101\/cshperspect.a031880","volume":"8","author":"DB Smith","year":"2018","unstructured":"Smith DB, Simmonds P. Classification and genomic diversity of enterically transmitted hepatitis viruses. Cold Spring Harbor Perspect Med. 2018;8(9):a031880.","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"1","key":"269_CR112","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3748\/wjg.v28.i1.76","volume":"28","author":"R Dunn","year":"2022","unstructured":"Dunn R, et al. Viral hepatitis in 2021: the challenges remaining and how we should tackle them. World J Gastroenterol. 2022;28(1):76.","journal-title":"World J Gastroenterol"},{"key":"269_CR113","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/0264-410X(93)90151-M","volume":"11","author":"D Shouval","year":"1993","unstructured":"Shouval D, et al. Single and booster dose responses to an inactivated hepatitis a virus vaccine: comparison with immune serum globulin prophylaxis. Vaccine. 1993;11:S9\u201314.","journal-title":"Vaccine"},{"issue":"5","key":"269_CR114","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/v15051080","volume":"15","author":"F Gabrielli","year":"2023","unstructured":"Gabrielli F, et al. Treatment options for hepatitis A and E: a non-systematic review. Viruses. 2023;15(5):1080.","journal-title":"Viruses"},{"key":"269_CR115","doi-asserted-by":"crossref","unstructured":"Van Damme P, Hendrickx G. Hepatitis A vaccines. Pediatric Vaccines and Vaccinations: A European Textbook, 2021: pp. 115\u2013125.","DOI":"10.1007\/978-3-030-77173-7_12"},{"issue":"5","key":"269_CR116","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1080\/21645515.2020.1819742","volume":"17","author":"C Herzog","year":"2021","unstructured":"Herzog C, Van Herck K, Van Damme P. Hepatitis A vaccination and its immunological and epidemiological long-term effects\u2013a review of the evidence. Hum Vaccines Immunotherapeutics. 2021;17(5):1496\u2013519.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"4","key":"269_CR117","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/imj.13386","volume":"47","author":"W Mohsen","year":"2017","unstructured":"Mohsen W, Levy MT. Hepatitis a to E: what\u2019s new? Intern Med J. 2017;47(4):380\u20139.","journal-title":"Intern Med J"},{"issue":"6","key":"269_CR118","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.aohep.2020.07.005","volume":"19","author":"S Marciano","year":"2020","unstructured":"Marciano S, et al. Outbreak of hepatitis A in a post-vaccination era: high rate of co-infection with sexually transmitted diseases. Ann Hepatol. 2020;19(6):641\u20134.","journal-title":"Ann Hepatol"},{"issue":"6","key":"269_CR119","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.21873\/invivo.12168","volume":"34","author":"T Kanda","year":"2020","unstructured":"Kanda T, et al. Additive effects of zinc chloride on the suppression of hepatitis a virus replication by interferon in human hepatoma Huh7 cells. vivo. 2020;34(6):3301\u20138.","journal-title":"vivo"},{"issue":"16","key":"269_CR120","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2169\/internalmedicine.2231-18","volume":"58","author":"K Kakisaka","year":"2019","unstructured":"Kakisaka K, et al. Hepatitis B surface antibody titers at one and two years after hepatitis B virus vaccination in healthy young Japanese adults. Intern Med. 2019;58(16):2349\u201355.","journal-title":"Intern Med"},{"issue":"8","key":"269_CR121","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1128\/JVI.02528-09","volume":"84","author":"Y Ni","year":"2010","unstructured":"Ni Y, et al. The pre-s2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly. J Virol. 2010;84(8):3879\u201388.","journal-title":"J Virol"},{"issue":"1","key":"269_CR122","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/INF.0000000000001361","volume":"36","author":"F Zhu","year":"2017","unstructured":"Zhu F, et al. Comparative efficacy, safety and immunogenicity of Hepavax-Gene TF and Engerix-B recombinant hepatitis B vaccines in neonates in China. Pediatr Infect Dis J. 2017;36(1):94\u2013101.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"269_CR123","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/v12020126","volume":"12","author":"JK-T Ho","year":"2020","unstructured":"Ho JK-T, Jeevan-Raj B, Netter H-J. Hepatitis B virus (HBV) subviral particles as protective vaccines and vaccine platforms. Viruses. 2020;12(2):126.","journal-title":"Viruses"},{"issue":"7916","key":"269_CR124","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41586-022-04857-0","volume":"606","author":"J-H Park","year":"2022","unstructured":"Park J-H, et al. Structural insights into the HBV receptor and bile acid transporter NTCP. Nature. 2022;606(7916):1027\u201331.","journal-title":"Nature"},{"issue":"12","key":"269_CR125","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.3390\/vaccines11121862","volume":"11","author":"F Mahmood","year":"2023","unstructured":"Mahmood F, et al. HBV vaccines: advances and development. Vaccines. 2023;11(12):1862.","journal-title":"Vaccines"},{"key":"269_CR126","doi-asserted-by":"publisher","first-page":"513329","DOI":"10.3389\/fimmu.2020.00401","volume":"11","author":"RC Hoogeveen","year":"2020","unstructured":"Hoogeveen RC, Boonstra A. Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection. Front Immunol. 2020;11:513329.","journal-title":"Front Immunol"},{"key":"269_CR127","doi-asserted-by":"publisher","first-page":"104925","DOI":"10.1016\/j.antiviral.2020.104925","volume":"182","author":"S Tsukuda","year":"2020","unstructured":"Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020;182:104925.","journal-title":"Antiviral Res"},{"issue":"3","key":"269_CR128","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1053\/j.gastro.2014.05.010","volume":"147","author":"S Franco","year":"2014","unstructured":"Franco S, et al. Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus\u2013infected homosexual man. Gastroenterology. 2014;147(3):599\u2013601. e1.","journal-title":"Gastroenterology"},{"issue":"3","key":"269_CR129","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2055-6640(20)30329-0","volume":"3","author":"AM Hill","year":"2017","unstructured":"Hill AM, Nath S, Simmons B. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries. J Virus Eradication. 2017;3(3):117\u201323.","journal-title":"J Virus Eradication"},{"key":"269_CR130","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00430-010-0171-0","volume":"200","author":"F Alborino","year":"2011","unstructured":"Alborino F, et al. Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity. Med Microbiol Immunol. 2011;200:77\u201383.","journal-title":"Med Microbiol Immunol"},{"issue":"8","key":"269_CR131","doi-asserted-by":"publisher","first-page":"e977","DOI":"10.1002\/iid3.977","volume":"11","author":"A Adugna","year":"2023","unstructured":"Adugna A. Therapeutic strategies and promising vaccine for hepatitis C virus infection. Immun Inflamm Dis. 2023;11(8):e977.","journal-title":"Immun Inflamm Dis"},{"issue":"3","key":"269_CR132","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/rmv.1785","volume":"24","author":"EM Ka\u0142u\u017cna","year":"2014","unstructured":"Ka\u0142u\u017cna EM. MicroRNA-155 and microRNA\u2010196b: promising biomarkers in hepatitis C virus infection? Rev Med Virol. 2014;24(3):169\u201385.","journal-title":"Rev Med Virol"},{"issue":"6","key":"269_CR133","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1056\/NEJMoa2023345","volume":"384","author":"K Page","year":"2021","unstructured":"Page K, et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N Engl J Med. 2021;384(6):541\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"269_CR134","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.virol.2009.02.007","volume":"386","author":"VS Greco-Stewart","year":"2009","unstructured":"Greco-Stewart VS, Schissel E, Pelchat M. The Hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III. Virology. 2009;386(1):12\u20135.","journal-title":"Virology"},{"key":"269_CR135","unstructured":"Serrano BC. Comparing the long-term outcome of hepatitis delta and HBV monoinfection: Is HDV-infection really worse? in Poster: International Liver Congress, Berlin Germany. 2011."},{"issue":"10","key":"269_CR136","doi-asserted-by":"publisher","first-page":"e110143","DOI":"10.1371\/journal.pone.0110143","volume":"9","author":"A Goyal","year":"2014","unstructured":"Goyal A, Murray JM. The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology. PLoS ONE. 2014;9(10):e110143.","journal-title":"PLoS ONE"},{"issue":"9835","key":"269_CR137","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/S0140-6736(11)61849-7","volume":"379","author":"N Kamar","year":"2012","unstructured":"Kamar N, et al. Hepatitis E. Lancet. 2012;379(9835):2477\u201388.","journal-title":"Lancet"},{"issue":"6","key":"269_CR138","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jhep.2014.08.047","volume":"61","author":"P Behrendt","year":"2014","unstructured":"Behrendt P, et al. The impact of hepatitis E in the liver transplant setting. J Hepatol. 2014;61(6):1418\u201329.","journal-title":"J Hepatol"},{"key":"269_CR139","doi-asserted-by":"crossref","unstructured":"Yin X et al. Origin, antigenicity, and function of a secreted form of ORF2 in hepatitis E virus infection. Proceedings of the National Academy of Sciences, 2018. 115(18): pp. 4773\u20134778.","DOI":"10.1073\/pnas.1721345115"},{"issue":"37","key":"269_CR140","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.3748\/wjg.v26.i37.5543","volume":"26","author":"AT Aslan","year":"2020","unstructured":"Aslan AT, Balaban HY. Hepatitis E virus: epidemiology, diagnosis, clinical manifestations, and treatment. World J Gastroenterol. 2020;26(37):5543.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"269_CR141","first-page":"592","volume":"9","author":"Y Li","year":"2021","unstructured":"Li Y, et al. B cell-mediated humoral immunity in chronic hepatitis b infection. J Clin Translational Hepatol. 2021;9(4):592.","journal-title":"J Clin Translational Hepatol"},{"issue":"9744","key":"269_CR142","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(10)61030-6","volume":"376","author":"F-C Zhu","year":"2010","unstructured":"Zhu F-C, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376(9744):895\u2013902.","journal-title":"Lancet"},{"issue":"7","key":"269_CR143","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3390\/vaccines12070722","volume":"12","author":"C Hartley","year":"2024","unstructured":"Hartley C, et al. Hepatitis E vaccines updates. Vaccines. 2024;12(7):722.","journal-title":"Vaccines"},{"issue":"2","key":"269_CR144","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83\u2013100.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"269_CR145","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"PS Kowalski","year":"2019","unstructured":"Kowalski PS, et al. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27(4):710\u201328.","journal-title":"Mol Ther"},{"issue":"1","key":"269_CR146","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 2021;20(1):33.","journal-title":"Mol Cancer"},{"issue":"4","key":"269_CR147","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","volume":"33","author":"MA Liu","year":"2010","unstructured":"Liu MA. Immunologic basis of vaccine vectors. Immunity. 2010;33(4):504\u201315.","journal-title":"Immunity"},{"issue":"1","key":"269_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","volume":"34","author":"M Fotin-Mleczek","year":"2011","unstructured":"Fotin-Mleczek M, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. 2011;34(1):1\u201315.","journal-title":"J Immunother"},{"issue":"5","key":"269_CR149","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/apm.13215","volume":"130","author":"JF Guti\u00e9rrez-Bautista","year":"2022","unstructured":"Guti\u00e9rrez-Bautista JF, et al. Study of humoral and cellular immunity in vaccinated with mRNA\u20101273. Apmis. 2022;130(5):261\u20139.","journal-title":"Apmis"},{"issue":"18","key":"269_CR150","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.3390\/ijms21186582","volume":"21","author":"S Xu","year":"2020","unstructured":"Xu S, et al. mRNA vaccine era\u2014mechanisms, drug platform and clinical prospection. Int J Mol Sci. 2020;21(18):6582.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"269_CR151","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1021\/acs.bioconjchem.8b00443","volume":"29","author":"KH Loomis","year":"2018","unstructured":"Loomis KH, et al. In vitro transcribed mRNA vaccines with programmable stimulation of innate immunity. Bioconjug Chem. 2018;29(9):3072\u201383.","journal-title":"Bioconjug Chem"},{"issue":"12","key":"269_CR152","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/nbt.2436","volume":"30","author":"B Petsch","year":"2012","unstructured":"Petsch B, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza a virus infection. Nat Biotechnol. 2012;30(12):1210\u20136.","journal-title":"Nat Biotechnol"},{"issue":"7662","key":"269_CR153","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222\u20136.","journal-title":"Nature"},{"issue":"3","key":"269_CR154","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","volume":"26","author":"S Linares-Fern\u00e1ndez","year":"2020","unstructured":"Linares-Fern\u00e1ndez S, et al. Tailoring mRNA vaccine to balance innate\/adaptive immune response. Trends Mol Med. 2020;26(3):311\u201323.","journal-title":"Trends Mol Med"},{"issue":"8","key":"269_CR155","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s43587-024-00644-w","volume":"4","author":"B Dallan","year":"2024","unstructured":"Dallan B, et al. Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19. Nat Aging. 2024;4(8):1121\u201336.","journal-title":"Nat Aging"},{"key":"269_CR156","doi-asserted-by":"crossref","unstructured":"Fatima M, Park P-G, Hong K-J. Clinical advancements in mRNA vaccines against viral infections. Clin Immunol, 2024: p. 110424.","DOI":"10.1016\/j.clim.2024.110424"},{"key":"269_CR157","doi-asserted-by":"crossref","unstructured":"Pardi N, Krammer F. mRNA vaccines for infectious diseases\u2014advances, challenges and opportunities. Nat Rev Drug Discovery, 2024: pp. 1\u201324.","DOI":"10.1038\/s41573-024-01042-y"},{"issue":"7","key":"269_CR158","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3390\/pharmaceutics15071972","volume":"15","author":"N Al Fayez","year":"2023","unstructured":"Al Fayez N, et al. Recent advancement in mRNA vaccine development and applications. Pharmaceutics. 2023;15(7):1972\u2013p.","journal-title":"Pharmaceutics"},{"issue":"7872","key":"269_CR159","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","volume":"596","author":"PS Arunachalam","year":"2021","unstructured":"Arunachalam PS, et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021;596(7872):410\u20136.","journal-title":"Nature"},{"issue":"22","key":"269_CR160","doi-asserted-by":"publisher","first-page":"9031","DOI":"10.1158\/0008-5472.CAN-10-0699","volume":"70","author":"S Kreiter","year":"2010","unstructured":"Kreiter S, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010;70(22):9031\u201340.","journal-title":"Cancer Res"},{"issue":"1","key":"269_CR161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#","volume":"30","author":"I Hoerr","year":"2000","unstructured":"Hoerr I, et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000;30(1):1\u20137.","journal-title":"Eur J Immunol"},{"issue":"11","key":"269_CR162","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discovery. 2021;20(11):817\u201338.","journal-title":"Nat Rev Drug Discovery"},{"key":"269_CR163","doi-asserted-by":"publisher","first-page":"885371","DOI":"10.3389\/fimmu.2022.885371","volume":"13","author":"RJ Ladak","year":"2022","unstructured":"Ladak RJ, et al. The current Landscape of mRNA vaccines against viruses and cancer\u2013a mini review. Front Immunol. 2022;13:885371.","journal-title":"Front Immunol"},{"key":"269_CR164","doi-asserted-by":"crossref","unstructured":"Bhattacharya M et al. Bioengineering of Novel Non-Replicating mRNA (NRM) and Self-Amplifying mRNA (SAM) Vaccine Candidates Against SARS-CoV-2 Using Immunoinformatics Approach. 2022. 64(5): pp. 510\u2013525.","DOI":"10.1007\/s12033-021-00432-6"},{"key":"269_CR165","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/bs.adgen.2014.10.005","volume":"89","author":"LA Brito","year":"2015","unstructured":"Brito LA, et al. Self-amplifying mRNA vaccines. Adv Genet. 2015;89:179\u2013233.","journal-title":"Adv Genet"},{"key":"269_CR166","first-page":"31","volume":"440","author":"G Maruggi","year":"2022","unstructured":"Maruggi G, et al. Self-amplifying mRNA-Based Vaccine Technology and its Mode of Action. Curr Top Microbiol Immunol. 2022;440:31\u201370.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"269_CR167","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","volume":"5","author":"NA Jackson","year":"2020","unstructured":"Jackson NA, et al. The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines. 2020;5(1):11.","journal-title":"npj Vaccines"},{"key":"269_CR168","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","volume":"335","author":"KJ Hassett","year":"2021","unstructured":"Hassett KJ, et al. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J Controlled Release. 2021;335:237\u201346.","journal-title":"J Controlled Release"},{"key":"269_CR169","doi-asserted-by":"crossref","unstructured":"Assefi M et al. A state-of-the-art review on solid lipid nanoparticles as a nanovaccines delivery system. J Drug Deliv Sci Technol, 2023: p. 104623.","DOI":"10.1016\/j.jddst.2023.104623"},{"issue":"1","key":"269_CR170","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","volume":"20","author":"SH Kiaie","year":"2022","unstructured":"Kiaie SH, et al. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnol. 2022;20(1):276.","journal-title":"J Nanobiotechnol"},{"key":"269_CR171","first-page":"1","volume-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","author":"Y Lee","year":"2023","unstructured":"Lee Y, et al. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Experimental & Molecular Medicine; 2023. pp. 1\u201312."},{"issue":"2","key":"269_CR172","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/vaccines9020147","volume":"9","author":"E Bettini","year":"2021","unstructured":"Bettini E, Locci M. SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines. 2021;9(2):147.","journal-title":"Vaccines"},{"issue":"1","key":"269_CR173","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12951-024-02355-1","volume":"22","author":"M Natami","year":"2024","unstructured":"Natami M, et al. An overview on mRNA-based vaccines to prevent monkeypox infection. J Nanobiotechnol. 2024;22(1):86.","journal-title":"J Nanobiotechnol"},{"issue":"20","key":"269_CR174","doi-asserted-by":"publisher","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","volume":"121","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, et al. Lipids and lipid derivatives for RNA delivery. Chem Rev. 2021;121(20):12181\u2013277.","journal-title":"Chem Rev"},{"issue":"12","key":"269_CR175","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen S et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. Iscience, 2021. 24(12).","journal-title":"Iscience"},{"issue":"1","key":"269_CR176","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12929-024-01000-1","volume":"31","author":"B Zhang","year":"2024","unstructured":"Zhang B, et al. Engineered EVs with pathogen proteins: promising vaccine alternatives to LNP-mRNA vaccines. J Biomed Sci. 2024;31(1):9.","journal-title":"J Biomed Sci"},{"issue":"2","key":"269_CR177","doi-asserted-by":"publisher","first-page":"103458","DOI":"10.1016\/j.drudis.2022.103458","volume":"28","author":"AA Aljabali","year":"2023","unstructured":"Aljabali AA, et al. Current state of, prospects for, and obstacles to mRNA vaccine development. Drug Discovery Today. 2023;28(2):103458.","journal-title":"Drug Discovery Today"},{"issue":"4","key":"269_CR178","doi-asserted-by":"publisher","first-page":"e01612","DOI":"10.1128\/mbio.01612-22","volume":"13","author":"B Chen","year":"2022","unstructured":"Chen B, et al. A single dose of Anti-HBsAg antibody-encoding mRNA-LNPs suppressed HBsAg expression: a potential cure of chronic hepatitis B virus infection. MBio. 2022;13(4):e01612\u201322.","journal-title":"MBio"},{"issue":"3","key":"269_CR179","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/vaccines12030237","volume":"12","author":"D De Pooter","year":"2024","unstructured":"De Pooter D, et al. mRNA therapeutic vaccine for Hepatitis B demonstrates immunogenicity and efficacy in the AAV-HBV Mouse Model. Vaccines. 2024;12(3):237.","journal-title":"Vaccines"},{"key":"269_CR180","volume-title":"Preclinical evaluation of therapeutic pDNA and mRNA vaccines for chronic hepatitis B","author":"D De Pooter","year":"2024","unstructured":"De Pooter D, Delputte P, Van Gulck E. Preclinical evaluation of therapeutic pDNA and mRNA vaccines for chronic hepatitis B. University of Antwerp; 2024."},{"issue":"1","key":"269_CR181","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41392-024-01871-8","volume":"9","author":"W Zai","year":"2024","unstructured":"Zai W, et al. Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection. Signal Transduct Target Therapy. 2024;9(1):150.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"269_CR182","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41541-023-00635-9","volume":"8","author":"T Patra","year":"2023","unstructured":"Patra T, et al. Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity. npj Vaccines. 2023;8(1):42.","journal-title":"npj Vaccines"},{"issue":"1","key":"269_CR183","doi-asserted-by":"publisher","first-page":"57","DOI":"10.29252\/ibj.23.1.57","volume":"23","author":"Z Sharifnia","year":"2019","unstructured":"Sharifnia Z, et al. Design and development of modified mRNA encoding core antigen of hepatitis C virus: a possible application in vaccine production. Iran Biomed J. 2019;23(1):57.","journal-title":"Iran Biomed J"},{"issue":"6","key":"269_CR184","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/sj.gt.3302184","volume":"11","author":"L Frelin","year":"2004","unstructured":"Frelin L, et al. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3\/4A gene. Gene Ther. 2004;11(6):522\u201333.","journal-title":"Gene Ther"},{"issue":"12","key":"269_CR185","doi-asserted-by":"publisher","first-page":"e00523","DOI":"10.1128\/jvi.00523-22","volume":"96","author":"V Vijayamahantesh","year":"2022","unstructured":"Vijayamahantesh V, et al. Modified E2 glycoprotein of hepatitis C virus enhances proinflammatory cytokines and protective immune response. J Virol. 2022;96(12):e00523\u201322.","journal-title":"J Virol"},{"key":"269_CR186","doi-asserted-by":"crossref","unstructured":"Costa GL, Sautto GA. Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response. Expert Rev Vaccines, 2025(just-accepted).","DOI":"10.1080\/14760584.2025.2452955"},{"key":"269_CR187","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12934-017-0812-8","volume":"16","author":"N Behloul","year":"2017","unstructured":"Behloul N, et al. Effects of mRNA secondary structure on the expression of HEV ORF2 proteins in Escherichia coli. Microb Cell Fact. 2017;16:1\u201314.","journal-title":"Microb Cell Fact"},{"issue":"1","key":"269_CR188","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/v15010214","volume":"15","author":"A Elbahrawy","year":"2023","unstructured":"Elbahrawy A, et al. Recent advances in Protective vaccines against Hepatitis viruses: a narrative review. Viruses. 2023;15(1):214.","journal-title":"Viruses"},{"issue":"1","key":"269_CR189","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emi.2013.54","volume":"2","author":"A Hekele","year":"2013","unstructured":"Hekele A, et al. Rapidly produced SAM\u00ae vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infections. 2013;2(1):1\u20137.","journal-title":"Emerg Microbes Infections"},{"issue":"6","key":"269_CR190","doi-asserted-by":"publisher","first-page":"e0004746","DOI":"10.1371\/journal.pntd.0004746","volume":"10","author":"M Schnee","year":"2016","unstructured":"Schnee M, et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis. 2016;10(6):e0004746.","journal-title":"PLoS Negl Trop Dis"},{"key":"269_CR191","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","volume":"217","author":"O Andries","year":"2015","unstructured":"Andries O, et al. N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Controlled Release. 2015;217:337\u201344.","journal-title":"J Controlled Release"},{"issue":"2","key":"269_CR192","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3 K, et al. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165\u201375.","journal-title":"Immunity"},{"issue":"9","key":"269_CR193","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.it.2018.04.002","volume":"39","author":"JM Allaire","year":"2018","unstructured":"Allaire JM, et al. The intestinal epithelium: central coordinator of mucosal immunity. Trends Immunol. 2018;39(9):677\u201396.","journal-title":"Trends Immunol"},{"issue":"1","key":"269_CR194","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/imr.12189","volume":"260","author":"C Gutzeit","year":"2014","unstructured":"Gutzeit C, Magri G, Cerutti A. Intestinal IgA production and its role in host-microbe interaction. Immunol Rev. 2014;260(1):76\u201385.","journal-title":"Immunol Rev"},{"issue":"6","key":"269_CR195","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1517\/17425247.2014.901308","volume":"11","author":"RP Deering","year":"2014","unstructured":"Deering RP, et al. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv. 2014;11(6):885\u201399.","journal-title":"Expert Opin Drug Deliv"},{"key":"269_CR196","volume-title":"mRNA Vaccine Era\u2014Mechanisms","author":"S Xu","year":"2020","unstructured":"Xu S, et al. mRNA vaccine era\u2014mechanisms. Drug Platform and Clinical Prospection; 2020."},{"issue":"11","key":"269_CR197","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4161\/rna.22269","volume":"9","author":"T Schlake","year":"2012","unstructured":"Schlake T, et al. Developing mRNA-vaccine technologies. RNA Biol. 2012;9(11):1319\u201330.","journal-title":"RNA Biol"},{"issue":"12","key":"269_CR198","doi-asserted-by":"publisher","first-page":"1906128","DOI":"10.1002\/adma.201906128","volume":"32","author":"S Ramishetti","year":"2020","unstructured":"Ramishetti S, et al. A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes. Adv Mater. 2020;32(12):1906128.","journal-title":"Adv Mater"},{"issue":"5","key":"269_CR199","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/eji.200425656","volume":"35","author":"B Scheel","year":"2005","unstructured":"Scheel B, et al. Toll-like receptor\u2010dependent activation of several human blood cell types by protamine\u2010condensed mRNA. Eur J Immunol. 2005;35(5):1557\u201366.","journal-title":"Eur J Immunol"},{"issue":"6","key":"269_CR200","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ccell.2019.05.005","volume":"35","author":"J Qiao","year":"2019","unstructured":"Qiao J, et al. Targeting tumors with IL-10 prevents dendritic cell-mediated CD8\u2009+\u2009T cell apoptosis. Cancer Cell. 2019;35(6):901\u201315. e4.","journal-title":"Cancer Cell"},{"key":"269_CR201","first-page":"100013","volume":"3","author":"VP Chavda","year":"2021","unstructured":"Chavda VP, et al. Darunavir ethanolate: repurposing an anti-HIV drug in COVID-19 treatment. Eur J Med Chem Rep. 2021;3:100013.","journal-title":"Eur J Med Chem Rep"},{"issue":"7","key":"269_CR202","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1002\/jmv.27717","volume":"94","author":"VP Chavda","year":"2022","unstructured":"Chavda VP, Patel AB, Vaghasiya DD. SARS-CoV\u20102 variants and vulnerability at the global level. J Med Virol. 2022;94(7):2986\u20133005.","journal-title":"J Med Virol"},{"issue":"7","key":"269_CR203","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1016\/j.apsb.2022.03.011","volume":"12","author":"Q He","year":"2022","unstructured":"He Q, et al. mRNA cancer vaccines: advances, trends and challenges. Acta Pharm Sinica B. 2022;12(7):2969\u201389.","journal-title":"Acta Pharm Sinica B"},{"key":"269_CR204","first-page":"e932915","volume":"27","author":"DV Parums","year":"2021","unstructured":"Parums DV. mRNA vaccines and future epidemic, pandemic, and endemic zoonotic virus infections. Med Sci Monitor: Int Med J Experimental Clin Res. 2021;27:e932915\u20131.","journal-title":"Med Sci Monitor: Int Med J Experimental Clin Res"},{"key":"269_CR205","volume-title":"ARTHRITIS AND RHEUMATISM","author":"R Ravikumar","year":"2006","unstructured":"Ravikumar R, et al. Anti-TNF therapy in RA patients alters Hepatitis B vaccine responses. ARTHRITIS AND RHEUMATISM. WILEY-LISS DIV JOHN WILEY & SONS INC; 2006. 111 RIVER ST, HOBOKEN, NJ 07030 USA."},{"issue":"1","key":"269_CR206","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jhep.2021.02.029","volume":"75","author":"S-H Liao","year":"2021","unstructured":"Liao S-H, et al. Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan. J Hepatol. 2021;75(1):132\u201341.","journal-title":"J Hepatol"},{"issue":"5","key":"269_CR207","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.amepre.2021.04.029","volume":"61","author":"P-j Lu","year":"2021","unstructured":"Lu P-j, et al. Hepatitis B vaccination among adults with diabetes mellitus, US, 2018. Am J Prev Med. 2021;61(5):652\u201364.","journal-title":"Am J Prev Med"},{"issue":"6","key":"269_CR208","doi-asserted-by":"publisher","first-page":"831","DOI":"10.4254\/wjh.v7.i6.831","volume":"7","author":"N Echeverr\u00eda","year":"2015","unstructured":"Echeverr\u00eda N, et al. Hepatitis C virus genetic variability and evolution. World J Hepatol. 2015;7(6):831.","journal-title":"World J Hepatol"},{"issue":"6","key":"269_CR209","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.jhep.2020.12.028","volume":"74","author":"S Sridhar","year":"2021","unstructured":"Sridhar S, et al. Multimodal investigation of rat hepatitis E virus antigenicity: implications for infection, diagnostics, and vaccine efficacy. J Hepatol. 2021;74(6):1315\u201324.","journal-title":"J Hepatol"},{"issue":"16","key":"269_CR210","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1093\/nar\/gkw551","volume":"44","author":"A Ramanathan","year":"2016","unstructured":"Ramanathan A, Robb GB, Chan S-H. mRNA capping: biological functions and applications. Nucleic Acids Res. 2016;44(16):7511\u201326.","journal-title":"Nucleic Acids Res"},{"issue":"16","key":"269_CR211","doi-asserted-by":"publisher","first-page":"9051","DOI":"10.1093\/nar\/gkac722","volume":"50","author":"K Drazkowska","year":"2022","unstructured":"Drazkowska K, et al. 2\u2032-O-Methylation of the second transcribed nucleotide within the mRNA 5\u2032 cap impacts the protein production level in a cell-specific manner and contributes to RNA immune evasion. Nucleic Acids Res. 2022;50(16):9051\u201371.","journal-title":"Nucleic Acids Res"},{"issue":"6292","key":"269_CR212","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1126\/science.aad9868","volume":"352","author":"AG Hinnebusch","year":"2016","unstructured":"Hinnebusch AG, Ivanov IP, Sonenberg N. Translational control by 5\u2032-untranslated regions of eukaryotic mRNAs. Science. 2016;352(6292):1413\u20136.","journal-title":"Science"},{"issue":"2","key":"269_CR213","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/vaccines11020238","volume":"11","author":"AA Deviatkin","year":"2023","unstructured":"Deviatkin AA, et al. Cap-independent circular mRNA translation efficiency. Vaccines. 2023;11(2):238.","journal-title":"Vaccines"},{"issue":"477","key":"269_CR214","doi-asserted-by":"publisher","first-page":"eaat9143","DOI":"10.1126\/scitranslmed.aat9143","volume":"11","author":"SL Hewitt","year":"2019","unstructured":"Hewitt SL, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u03b3, and OX40L mRNAs. Sci Transl Med. 2019;11(477):eaat9143.","journal-title":"Sci Transl Med"},{"issue":"12","key":"269_CR215","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3390\/vaccines11121737","volume":"11","author":"R Okuyama","year":"2023","unstructured":"Okuyama R. mRNA and Adenoviral Vector Vaccine platforms utilized in COVID-19 vaccines: technologies, Ecosystem, and future directions. Vaccines. 2023;11(12):1737.","journal-title":"Vaccines"},{"issue":"2","key":"269_CR216","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","volume":"12","author":"A Wadhwa","year":"2020","unstructured":"Wadhwa A et al. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics, 2020. 12(2).","journal-title":"Pharmaceutics"},{"key":"269_CR217","volume-title":"mRNA vaccines: Past, present, future","author":"M Karam","year":"2022","unstructured":"Karam M, Daoud G. mRNA vaccines: past, present, future. Asian journal of pharmaceutical sciences; 2022."},{"issue":"3","key":"269_CR218","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1021\/acs.bioconjchem.6b00090","volume":"27","author":"B Li","year":"2016","unstructured":"Li B, Luo X, Dong Y. Effects of chemically modified messenger RNA on protein expression. Bioconjug Chem. 2016;27(3):849\u201353.","journal-title":"Bioconjug Chem"},{"key":"269_CR219","first-page":"77","volume":"15","author":"W Yihunie","year":"2023","unstructured":"Yihunie W, Nibret G, Aschale Y. Recent advances in Messenger Ribonucleic Acid (mRNA) vaccines and their Delivery systems: a review. Clin Pharmacology: Adv Appl, 2023: pp. 77\u201398.","journal-title":"Clin Pharmacology: Adv Appl"},{"issue":"1","key":"269_CR220","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/JAC.0000000000000360","volume":"44","author":"A Coustasse","year":"2021","unstructured":"Coustasse A, Kimble C, Maxik K. COVID-19 and vaccine hesitancy: a challenge the United States must overcome. J Ambul Care Manag. 2021;44(1):71\u20135.","journal-title":"J Ambul Care Manag"},{"issue":"4","key":"269_CR221","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1473-3099(21)00076-1","volume":"21","author":"A Ozonoff","year":"2021","unstructured":"Ozonoff A, Nanishi E, Levy O. Bell\u2019s palsy and SARS-CoV-2 vaccines. Lancet Infect Dis. 2021;21(4):450\u20132.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"269_CR222","doi-asserted-by":"publisher","first-page":"38","DOI":"10.56098\/ijvtpr.v2i1.23","volume":"2","author":"S Seneff","year":"2021","unstructured":"Seneff S, Nigh G. Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19. Int J Vaccine Theory Pract Res. 2021;2(1):38\u201379.","journal-title":"Int J Vaccine Theory Pract Res"},{"key":"269_CR223","doi-asserted-by":"publisher","first-page":"633776","DOI":"10.3389\/fcell.2021.633776","volume":"9","author":"F Qin","year":"2021","unstructured":"Qin F, et al. A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: from basic principles to current applications. Front cell Dev Biology. 2021;9:633776.","journal-title":"Front cell Dev Biology"},{"key":"269_CR224","doi-asserted-by":"publisher","first-page":"113834","DOI":"10.1016\/j.addr.2021.113834","volume":"178","author":"A Gupta","year":"2021","unstructured":"Gupta A, et al. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev. 2021;178:113834.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"269_CR225","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41467-025-55843-9","volume":"16","author":"CJ Maine","year":"2025","unstructured":"Maine CJ, et al. Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label phase I study in healthy volunteers. Nat Commun. 2025;16(1):456.","journal-title":"Nat Commun"},{"issue":"9\u201310","key":"269_CR226","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/smll.201201463","volume":"9","author":"A Pietroiusti","year":"2013","unstructured":"Pietroiusti A, Campagnolo L, Fadeel B. Interactions of engineered nanoparticles with organs protected by internal biological barriers. Small. 2013;9(9\u201310):1557\u201372.","journal-title":"Small"},{"issue":"1","key":"269_CR227","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1038\/s41467-024-46327-3","volume":"15","author":"AH Isaac","year":"2024","unstructured":"Isaac AH, et al. Impact of PEG sensitization on the efficacy of PEG hydrogel-mediated tissue engineering. Nat Commun. 2024;15(1):3283.","journal-title":"Nat Commun"},{"issue":"1","key":"269_CR228","doi-asserted-by":"publisher","first-page":"e70035","DOI":"10.1002\/mco2.70035","volume":"6","author":"X He","year":"2025","unstructured":"He X, et al. Nonviral targeted mRNA delivery: principles, progresses, and challenges. MedComm. 2025;6(1):e70035.","journal-title":"MedComm"},{"issue":"1","key":"269_CR229","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev-bioeng-110220-031722","volume":"24","author":"J Chen","year":"2022","unstructured":"Chen J, Chen J, Xu Q. Current developments and challenges of mRNA vaccines. Annu Rev Biomed Eng. 2022;24(1):85\u2013109.","journal-title":"Annu Rev Biomed Eng"},{"issue":"4","key":"269_CR230","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/v9040075","volume":"9","author":"T Tu","year":"2017","unstructured":"Tu T et al. HBV DNA integration: Molecular mechanisms and clinical implications. Viruses, 2017. 9(4).","journal-title":"Viruses"},{"issue":"10","key":"269_CR231","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.4254\/wjh.v13.i10.1234","volume":"13","author":"N Echeverr\u00eda","year":"2021","unstructured":"Echeverr\u00eda N, et al. In the era of rapid mRNA-based vaccines: why is there no effective hepatitis C virus vaccine yet? World J Hepatol. 2021;13(10):1234.","journal-title":"World J Hepatol"}],"container-title":["Biological Procedures Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12575-025-00269-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12575-025-00269-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12575-025-00269-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T12:02:23Z","timestamp":1748952143000},"score":1,"resource":{"primary":{"URL":"https:\/\/biologicalproceduresonline.biomedcentral.com\/articles\/10.1186\/s12575-025-00269-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":231,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["269"],"URL":"https:\/\/doi.org\/10.1186\/s12575-025-00269-2","relation":{},"ISSN":["1480-9222"],"issn-type":[{"value":"1480-9222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors consent to the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"20"}}